One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: Meta-analysis

Hiroyoshi Takeuchi, Navot Kantor, Marcos Sanches, Gagan Fervaha, Ofer Agid, Gary Remington

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Background: As definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome. Aims: To compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia. Method: Randomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included. Meta-regression analyses were employed using a mixed model. Results: A total of 11 studies involving 2826 patients were included. Meta-regression analyses revealed significant interactions between group and time (Ps<0.0001); both standardised total scores and per cent score changes remained almost unchanged in patients continuing antipsychotic treatment, whereas symptoms continuously worsened over time in those switching to placebo treatment. Conclusions: When considering long-term antipsychotic treatment of schizophrenia, clinicians must balance symptomatic and functional outcomes.

Original languageEnglish
Pages (from-to)137-143
Number of pages7
JournalBritish Journal of Psychiatry
Volume211
Issue number3
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Antipsychotic Agents
Meta-Analysis
Schizophrenia
Placebos
Therapeutics
Regression Analysis
Brief Psychiatric Rating Scale
Randomized Controlled Trials
Recurrence

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo : Meta-analysis. / Takeuchi, Hiroyoshi; Kantor, Navot; Sanches, Marcos; Fervaha, Gagan; Agid, Ofer; Remington, Gary.

In: British Journal of Psychiatry, Vol. 211, No. 3, 01.09.2017, p. 137-143.

Research output: Contribution to journalReview article

Takeuchi, Hiroyoshi ; Kantor, Navot ; Sanches, Marcos ; Fervaha, Gagan ; Agid, Ofer ; Remington, Gary. / One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo : Meta-analysis. In: British Journal of Psychiatry. 2017 ; Vol. 211, No. 3. pp. 137-143.
@article{0080a21de1de4867b93ed1f0925e35b3,
title = "One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: Meta-analysis",
abstract = "Background: As definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome. Aims: To compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia. Method: Randomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included. Meta-regression analyses were employed using a mixed model. Results: A total of 11 studies involving 2826 patients were included. Meta-regression analyses revealed significant interactions between group and time (Ps<0.0001); both standardised total scores and per cent score changes remained almost unchanged in patients continuing antipsychotic treatment, whereas symptoms continuously worsened over time in those switching to placebo treatment. Conclusions: When considering long-term antipsychotic treatment of schizophrenia, clinicians must balance symptomatic and functional outcomes.",
author = "Hiroyoshi Takeuchi and Navot Kantor and Marcos Sanches and Gagan Fervaha and Ofer Agid and Gary Remington",
year = "2017",
month = "9",
day = "1",
doi = "10.1192/bjp.bp.116.186007",
language = "English",
volume = "211",
pages = "137--143",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "3",

}

TY - JOUR

T1 - One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo

T2 - Meta-analysis

AU - Takeuchi, Hiroyoshi

AU - Kantor, Navot

AU - Sanches, Marcos

AU - Fervaha, Gagan

AU - Agid, Ofer

AU - Remington, Gary

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background: As definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome. Aims: To compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia. Method: Randomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included. Meta-regression analyses were employed using a mixed model. Results: A total of 11 studies involving 2826 patients were included. Meta-regression analyses revealed significant interactions between group and time (Ps<0.0001); both standardised total scores and per cent score changes remained almost unchanged in patients continuing antipsychotic treatment, whereas symptoms continuously worsened over time in those switching to placebo treatment. Conclusions: When considering long-term antipsychotic treatment of schizophrenia, clinicians must balance symptomatic and functional outcomes.

AB - Background: As definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome. Aims: To compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia. Method: Randomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included. Meta-regression analyses were employed using a mixed model. Results: A total of 11 studies involving 2826 patients were included. Meta-regression analyses revealed significant interactions between group and time (Ps<0.0001); both standardised total scores and per cent score changes remained almost unchanged in patients continuing antipsychotic treatment, whereas symptoms continuously worsened over time in those switching to placebo treatment. Conclusions: When considering long-term antipsychotic treatment of schizophrenia, clinicians must balance symptomatic and functional outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85028750729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028750729&partnerID=8YFLogxK

U2 - 10.1192/bjp.bp.116.186007

DO - 10.1192/bjp.bp.116.186007

M3 - Review article

C2 - 28522434

AN - SCOPUS:85028750729

VL - 211

SP - 137

EP - 143

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - 3

ER -